Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Ph.D., Harvard Medical School 2005
  • B.S., Pennsylvania State University 1999
• Research
• 

  Selected Grants

  • Awakening the dormant tumor: the role of the tumor microenvironment in breast cancer recurrence awarded by National Institutes of Health 2017 - 2021
  • Par-4 Regulation and Function in Breast Cancer Dormancy and Recurrence awarded by National Institutes of Health 2016 - 2021
  • The Role of Epigenetic Plasticity in Breast Cancer Recurrence awarded by National Institutes of Health 2018 - 2021
  • Genetics Training Grant awarded by National Institutes of Health 1979 - 2020
  • Organization and Function of Cellular Structure awarded by National Institutes of Health 1975 - 2020
  • Pharmacological Sciences Training Program awarded by National Institutes of Health 1975 - 2020
  • Pathways regulating dormant cell survival and recurrence awarded by American Cancer Society, Inc. 2019
  • Pharmacology Industry Internships for Ph.D. Students awarded by American Society for Pharmacology and Experimental Therapeutics 2017 - 2019
• Publications & Artistic Works
• 

  Selected Publications

  • Conference Papers

    • Damrauer, J, and Alvarez, JV. "Clonal dynamics during breast cancer dormancy and recurrence." AACR Special Conference on Advances in Modeling Cancer in Mice - Technology, Biology, and Beyond. Orlando, FL. September 24, 2018 - September 27, 2018.: AMER ASSOC CANCER RESEARCH, May 1, 2018.  Link to Item

  • Journal Articles

    • Mabe, NW, Fox, DB, Lupo, R, Decker, AE, Phelps, SN, Thompson, JW, and Alvarez, JV. "Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer." The Journal of Clinical Investigation 128, no. 10 (October 2018): 4413-4428.  Full Text
    • Damrauer, JS, Phelps, SN, Amuchastegui, K, Lupo, R, Mabe, NW, Walens, A, Kroger, BR, and Alvarez, JV. "Foxo-dependent Par-4 Upregulation Prevents Long-term Survival of Residual Cells Following PI3K-Akt Inhibition." Molecular cancer research : MCR (January 12, 2018).  Full Text
    • Alvarez, JV, Belka, GK, Pan, T-C, Chen, C-C, Blankemeyer, E, Alavi, A, Karp, JS, and Chodosh, LA. "Oncogene pathway activation in mammary tumors dictates FDG-PET uptake." Cancer Research 74, no. 24 (December 2014): 7583-7598.  Full Text
    • Feng, Y, Pan, T-C, Pant, DK, Chakrabarti, KR, Alvarez, JV, Ruth, JR, and Chodosh, LA. "SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling." Cancer discovery 4, no. 7 (July 2014): 790-803.  Full Text
    • Alvarez, JV, Pan, T-C, Ruth, J, Feng, Y, Zhou, A, Pant, D, Grimley, JS, Wandless, TJ, Demichele, A, I-SPY 1 TRIAL Investigators, , and Chodosh, LA. "Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy." Cancer cell 24, no. 1 (July 2013): 30-44.  Full Text
    • Chen, C-C, Stairs, DB, Boxer, RB, Belka, GK, Horseman, ND, Alvarez, JV, and Chodosh, LA. "Autocrine prolactin induced by the Pten-Akt pathway is required for lactation initiation and provides a direct link between the Akt and Stat5 pathways." Genes & development 26, no. 19 (October 2012): 2154-2168.  Full Text
    • Alvarez, JV, Yeh, ES, Feng, Y, and Chodosh, LA. "Oncogene addiction: Mouse models and clinical relevance for molecularly targeted therapies." (January 1, 2012): 527-547. (Chapter)  Full Text
    • Chen, C-C, Boxer, RB, Stairs, DB, Portocarrero, CP, Horton, RH, Alvarez, JV, Birnbaum, MJ, and Chodosh, LA. "Akt is required for Stat5 activation and mammary differentiation." Breast Cancer Research : Bcr 12, no. 5 (January 2010): R72-null.  Full Text
    • Chen, C-C, Boxer, RB, Stairs, DB, Portocarrero, CP, Horton, RH, Alvarez, JV, Birnbaum, MJ, and Chodosh, LA. "Akt is required for Stat5 activation and mammary differentiation." Breast cancer research : BCR 12, no. 5 (2010): R72-.  Full Text
    • Liu, Z, Wang, M, Alvarez, JV, Bonney, ME, Chen, C-C, D'Cruz, C, Pan, T-C, Tadesse, MG, and Chodosh, LA. "Singular value decomposition-based regression identifies activation of endogenous signaling pathways in vivo." Genome biology 9, no. 12 (January 2008): R180-.  Full Text
    • Alvarez, JV, Perez, D, and Chodosh, LA. "mILC-ing the mouse mammary gland: A model for invasive lobular carcinoma." Cancer cell 10, no. 5 (November 2006): 347-349.  Full Text
    • Ishii, Y, Pirkmaier, A, Alvarez, JV, Frank, DA, Keselman, I, Logothetis, D, Mandeli, J, O'Connell, MJ, Waxman, S, and Germain, D. "Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model." Jnci Journal of the National Cancer Institute 98, no. 17 (September 2006): 1238-1247.  Full Text
    • Liddle, FJ, Alvarez, JV, Poli, V, and Frank, DA. "Tyrosine phosphorylation is required for functional activation of disulfide-containing constitutively active STAT mutants." Biochemistry 45, no. 17 (May 2006): 5599-5605.  Full Text
    • Alvarez, JV, Greulich, H, Sellers, WR, Meyerson, M, and Frank, DA. "Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor." Cancer Research 66, no. 6 (March 2006): 3162-3168.  Full Text
    • Greulich, H, Chen, T-H, Feng, W, Jänne, PA, Alvarez, JV, Zappaterra, M, Bulmer, SE, Frank, DA, Hahn, WC, Sellers, WR, and Meyerson, M. "Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants." Plos Medicine 2, no. 11 (November 2005): e313-null.  Full Text
    • Alvarez, JV, Febbo, PG, Ramaswamy, S, Loda, M, Richardson, A, and Frank, DA. "Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors." Cancer research 65, no. 12 (June 2005): 5054-5062.  Full Text
    • Nelson, EA, Walker, SR, Alvarez, JV, and Frank, DA. "Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification." The Journal of biological chemistry 279, no. 52 (December 2004): 54724-54730.  Full Text
    • Alvarez, JV, and Frank, DA. "Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis." Cancer biology & therapy 3, no. 11 (November 22, 2004): 1045-1050. (Review)  Full Text
• Teaching & Mentoring
• 

  Recent Courses

  • CMB 710A: Cell & Molecular Biology Module I 2018
  • MOLCAN 819: Cancer as a Disease 2018
  • PHARM 394: Research Independent Study 2018
  • PHARM 493: Research Independent Study 2018
  • PHARM 494: Research Independent Study 2018

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.